Insulin glargine doesn't affect cancer rate in diabetes

06/27/2013 | MedPage Today (free registration) · Healio

Insulin glargine did not increase the incidence of cancer in patients with prediabetes and diabetes, researchers reported at the ADA 73rd Scientific Sessions. Data showed the rate of cancer was 1.32 per 100 person-years in the glargine and standard care groups at six years, while the unadjusted rates of cancer-related mortality were 0.54 per 100 person-years in the standard group and 0.51 per 100 person-years in the glargine group.

View Full Article in:

MedPage Today (free registration) · Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN